ISO 15189:2012 accredited and JCI certified

TESTING RvA M 140

Department of Pathology UMC Utrecht APPLICATION FORM for Molecular Pathology

SEND TO
Department of Pathology UMC Utrecht
Attn Molecular Pathology
Roomnumber H04.312
Heidelberglaan 100
3584 CX Utrecht
The Netherlands

UMC Utrecht

Patient information

Name + initials:

Adress:

Date of birth:

Gender:

Citizen Service Number (BSN):

Patient administration
Tel +31 (0)88 7557615
Fax +31 (0)88 7569588
E-mail administratie-pathologie@umcutrecht.nl

Molecular Pathology
Tel +31 (0)88 7574252
E-mail pathology-moleculardiagnostics@umcutrecht.nl

PATHOLOGY UMC UTRECHT:

Requesting laboratory and/or physician

Name :

Department :

Institution/country :

Date :

External PA- and/or reference number :

Material
H&E stained slide
FFPE block :
Fresh frozen* :
DNA :
Other :
Slides**

*Tick the box in case of fresh frozen for PMC: ☐

**In case of slides: for non-FISH applications: 10 unstained sections 4µm (coated slides)
for FISH applications: 6 unstained sections 4µm (coated slides)

REMARKS:

NGS

☐ BRCA 1/2 (somatic)	
☐ CLL (chronic lymphatic leukemia)	TP53
☐ Colon	BRAF/RAS
☐ Desmoid tumor	CTNNB1
☐ TERT	Glioma panel
☐ GIST	KIT/PDGFRA/BRAF
☐ Glioma	e.g. IDH1/IDH2/1p19q codeletion
☐ Hematological diseases	e.g. SF3B1/SRSF2/U2AF1/TET2/ SXL1/EZH2
☐ LPL (lymphoplasmacytic lymphoma)	MYD88
☐ Melanoma	BRAF/HRAS/NRAS/KIT
☐ Melanocytic lesions	APC/BRAF/CTNNB1/GNA11/GNAQ/ HRAS/IDH1/KIT/NRAS/TERT
☐ MPN (myeloproliferative neoplasms)	CALR/MPL/JAK2
☐ Kidney panel (PMC)	TP53/WT1/WTX/FBXW7/SMARCB1/ SMARCA4
☐ Thyroid carcinoma	BRAF/RAS
☐ TP53/Tumorclonality	TP53
☐ Other	Indicate genes of interest at remarks

Lung:

☐ Adenocarcinoma*/non-small cell lung cancer (NSCLC)**	KRAS/EGFR/BRAF/HER2
☐ Squamous cell carcinoma***	KRAS/FGFR1 (mut + amp)
☐ cMET exon 14 skipping	
☐ EGFR TKI resistance	EGFR/HER2 (mut)/cMET (amp)
☐ ALK/ROS1 inhibitors	ALK (mut)

Predictive IHC
☐ PD-L1
☐ Pan-NTRK

RT-PCR

☐ KIAA-BRAF	
☐ YWHAE-FAM22A/B	
☐ EWSR1	FL1/ERG/WT1

Other molecular analyses

☐ BRAF cobas	Only V600E
☐ HPV cobas 4800	High risk****
☐ HPV Linear Array genotyping assay	High risk + low risk****
☐ B-cel clonality	
☐ T-cel clonality	
☐ Tissue-identification	
☐ Neuroblastoma	SNP: 1p/17q/ALK, FISH: N-MYC, NGS: ALK
☐ PNET V medulloblastoma	IHC: CTNNB1 + p53, FISH: cMYC/N-MYC/CEN6, NGS

ddPCR
☐ BRAF p.(V600E)
☐ EGFR exon 19 deletions
☐ EGFR p.(L858R)
☐ EGFR resistance p.(T790M)
☐ MYD88 p.(L265P)

Arrays

☐ SNP array	e.g. Wilms tumor, clonality, etc.
☐ Methylation profiling	Classification of CNS tumors

Please turn over for FISH, MSI, MLPA and DNA-isolation

Department of Pathology UMC Utrecht APPLICATION FORM for Molecular Pathology

Fluorescence In Situ Hybridisation

Soft tissue

☐ CHOP	Break-apart
☐ EWSR1	Break-apart + fusion FLI1
☐ FKHR (FOXO1)	Break-apart
☐ FUS	Break-apart
☐ MDM2	Break-apart
☐ SYT	Break-apart

Lymphoma

☐ BCL-2	Break-apart
☐ BCL6	Break-apart
☐ cMYC	Break-apart + fusion IgH
☐ CCND1 (Cyclin-D1)	Break-apart
☐ MALT1	Break-apart

Chromosomes

☐ Centromere X/Y/18
☐ Centromere 13/18/21

Other

☐ ALK	Break-apart
☐ BCOR	Break-apart
☐ cMET	Amplification
☐ COL1A1-PDGFB	Fusion
☐ ERBB2 (Her2neu)	Amplification
☐ ETV6	Break-apart
☐ FGFR1	Break-apart + amplification
☐ FGFR3	Break-apart + amplification
☐ HMGA2	Break-apart
☐ MAML2	Break-apart
☐ MUM1 (IRF4)	Break-apart
☐ MYB	Break-apart
☐ N-MYC	Amplification
☐ NRG1	Break-apart
☐ NTRK 1/2/3	Break-apart
☐ PLAG1	Break-apart
☐ PLAG1/CTNNB1	Fusion
☐ RET	Break-apart
☐ ROS1	Break-apart
☐ TFE3	Break-apart
☐ USP6	Break-apart
☐ Research ISH	Indicate gene of interest at remarks

MSI for Lynch syndrome
(IHC MMR proteins + mol. markers)

☐ MSI Lynch tumor tissue*****
☐ MSI Lynch normal tissue*****
☐ MSI Lynch tumor/normal tissue
☐ MLH1 hypermethylation and
BRAF Mutation analysis (only V600E) for MSI

MSI for therapeutic purposes
(IHC MMR proteins)

☐ Only tumor tissue

DNA-isolation

☐ DNA-isolation tumor tissue
☐ DNA-isolation normal tissue
☐ DNA-isolation other, ... e.g. blood

MLPA

☐ MLPA 1p19q codeletion
☐ MLPA FGFR
☐ MLPA Her2neu
☐ MLPA MDM2/CDK4
☐ MLPA Trisomy 13/18/21/X/Y
☐ MLPA Wilms tumors

☐ MS-MLPA BRCA1 hypermethylation
☐ MS-MLPA MGMT promotermethylation

* For lung applications: also send a distinctive staining, e.g. TTF1, together with your application
** If no mutations are found in KRAS and/or EGFR for adenocarcinoma/NSCLC, additional translocation analysis will be performed (according to agreement)
*** If no mutations are found in KRAS and/or FGFR1 for squamous cell carcinoma an additional ALK analysis will be performed
**** For all HPV applications:
Severe dysplasia/CIS/invasive: apply for HPV cobas 4800
Low/moderate dysplasia//verrucous: apply for HPV Linear Array genotyping assay
***** For molecular markers, tumor and normal tissue is necessary. When only tumor is present, IHC will be performed